Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Heart abnormalities revealed in COVID-19 patients
Mon July 13th - Half of COVID-19 patients who had a heart scan in hospital were diagnosed with abnormalities in their heart function, a study reveals today. More
Shame and sorrow as UK's clinician deaths topped only by Russia
Mon July 13th - The UK has suffered one of the highest loss rates of health and social care workers from the COVID-19 virus, according to a major global report published today. More
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...

Antibody breakthrough for Alzheimer's disease

Tuesday May 26th, 2020

An antibody has been designed that can identify the toxic particles that destroy healthy brain cells in Alzheimer's disease, it has been announced.

Designed by a team from the University of Cambridge, University College London, UK, and Lund University, Sweden, the antibody is highly accurate at detecting toxic oligomers and quantifying their numbers.

Writing in the latest edition of Proceedings of the National Academy of Sciences (PNAS), the researchers say the discovery of an antibody to accurately target oligomers is an important step to monitor the disease, identify its cause, and control it.

Lead researcher Professor Michele Vendruscolo from Cambridge's Centre for Misfolding Diseases, said: “There is an urgent unmet need for quantitative methods to recognise oligomers, which play a major role in Alzheimer's disease, but are too elusive for standard antibody discovery strategies.

“Through our innovative design strategy, we have now discovered antibodies to recognise these toxic particles.”

Oligomers have been identified as the most likely cause of dementia. Although proteins are normally responsible for important cell processes, according to the amyloid hypothesis, but when people have Alzheimer's disease proteins, including specifically amyloid-beta proteins, become rogue and kill healthy nerve cells.

“While the amyloid hypothesis is a prevalent view, it has not been fully validated in part because amyloid-beta oligomers are so difficult to detect, so there are differing opinions on what causes Alzheimer's disease,” said Prof Vendruscolo.

“The discovery of an antibody to accurately target oligomers is, therefore, an important step to monitor the progression of the disease, identify its cause, and eventually keep it under control.”

The inability to detect oligomers has been a major obstacle in the progress of Alzheimer's research, hampering the development of effective diagnostic and therapeutic interventions.

The new method is based on an approach for antibody discovery developed over the last ten years at the Centre for Misfolding Diseases, enabling the design of antibodies for challenging antigens, including those that live for a very short time.

The researchers used a design strategy to target the epitopes of the oligomers in vitro and in vivo experiments to create an antibody with at least three orders of magnitude greater affinity for the oligomers over other forms of amyloid-beta.

This, say the research team, is the key feature that enables the antibody to specifically quantify oligomers in both in vitro and in vivo samples.

Study first author Dr Francesco Aprile said: “Our method allows the generation of antibody molecules able to target oligomers despite their heterogeneity, and we hope it could be a significant step towards new diagnostic approaches.”

PNAS 25 May 20202

Tags: Brain & Neurology | UK News

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)